| Date Filed | Type | Description |
| 07/31/2019 |
SC 13D/A
| Niihara Yutaka reports a 0% stake in EMI Holding, Inc. |
| 07/22/2019 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 07/22/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 07/12/2019 |
4
| ZEN Wei Peu (Director) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Bought 303,030 shares
@ $6.6, valued at
$2M
Bought 151,515 shares
@ $6.6, valued at
$1000k
|
|
| 07/11/2019 |
4
| Niihara Yutaka (Chairman and CEO) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Acquired 1 options to buy
@ $10, valued at
$10
Acquired 1 options to buy
@ $10, valued at
$10 |
|
| 07/08/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/08/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/03/2019 |
8-K
| Other Events, Financial Statements and Exhibits |
| 07/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/24/2019 |
8-K
| Quarterly results |
| 06/24/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 06/21/2019 |
4
| Sherwood Joseph Charles III (CFO) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Granted 1 options
@ $10.3, valued at
$10.3 |
|
| 06/14/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 06/03/2019 |
3
| Sherwood Joseph Charles III (CFO) has filed a Form 3 on EMMAUS LIFE SCIENCES, INC. |
| 05/31/2019 |
4
| Niihara Yutaka (Chairman and CEO) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Bought 5,000 shares
@ $10, valued at
$50k
|
|
| 05/14/2019 |
10-Q
| Quarterly Report for the period ended March 31, 2019 |
| 03/21/2019 |
10-K
| Annual Report for the period ended December 31, 2018 |
| 03/11/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 03/11/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/07/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/04/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/29/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/24/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/14/2019 |
SC 13D/A
| Niihara Yutaka reports a 31.6% stake in Emmaus Life Sciences, Inc. |
| 01/10/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/07/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 01/07/2019 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits|
Docs:
|
"Agreement and Plan of Merger and Reorganization, by and among MYnd Analytics, Inc., Athena Merger Subsidiary, Inc. and Emmaus Life Sciences, Inc",
"Form of Emmaus Voting Agreement, including form of irrevocable proxy",
"Form of MYnd Voting Agreement, including form of irrevocable proxy",
"Form of Emmaus Lock-Up Agreement",
"Form of MYnd Lock-Up Agreement",
"CFO, Emmaus Life Sciences, Inc." |
|
| 01/07/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/21/2018 |
3/A
| ZEN Wei Peu (Director) has filed a Form 3/A on EMMAUS LIFE SCIENCES, INC. |
| 12/20/2018 |
4
| ZEN Wei Peu (Director) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Bought 100,000 shares
@ $10, valued at
$1M
|
|
| 12/20/2018 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits |
| 12/14/2018 |
4
| Niihara Yutaka (Chairman and CEO) has filed a Form 4 on EMMAUS LIFE SCIENCES, INC.|
Txns:
| Bought 5,000 shares
@ $10, valued at
$50k
|
|
| 12/14/2018 |
SC 13D/A
| Niihara Yutaka reports a 31.6% stake in Emmaus Life Sciences, Inc. |
| 11/30/2018 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
|